Sagimet Biosciences Inc. Income Statement
SGMT|2 years of annual SEC 10-K data (FY2023-FY2024)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 2 fiscal years. All figures from audited SEC 10-K filings.
Sagimet Biosciences Inc. reported $2M in revenue and $28M in net loss for FY2024. Revenue increased 0.0% from FY2023 to FY2024.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score 0.63 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2024 | FY2023 |
|---|---|---|
| Revenue | $2.0M | $2.0M |
| SG&A Expense | $13.0M | $6.1M |
| R&D Expense | $19.8M | $24.9M |
| Operating Income | -$30.7M | -$31.1M |
| Net Income | -$27.9M | -$30.5M |
| EPS (Basic) | -$2.66 | -$165.20 |
| EPS (Diluted) | -$2.66 | -$165.20 |
| Shares Outstanding | 10.5M | 185.1K |
| Operating Margin | -1537.0% | -1552.8% |
| Profit Margin | -1393.8% | -1525.0% |